Biochip, and method for the selective identification of
The present invention relates to a method for the selective identification of Chlamydia trachomatis infections wherein the antigens CT017, CT098, CT318-L1 P, CT431-TARP, CT603-TSAP, and CT664 are used for the specific identification of Chlamydia trachomatis antibodies in samples from mammals. The method according to the invention facilitates the selective identification method of identification of Chlamydia trachomatis infections, in which no false positive results are generated by other Chlamydia species such as, for example, Chlamydia pneumoniae . The invention further relates to a biochip which has the aforementioned Chlamydia trachomatis -specific antigens for the identification of antibodies. The biochip with antigens according to the invention is suitable for multiparameter identification methods in particular.
1. A test kit for the selective detection of Chlamydia trachomatis infections and the serological differentiation among acute Chlamydia pneumoniae infection, acute Chlamydia trachomatis infection and chronic Chlamydia trachomatis infection, said kit consisting of two to seven antigens selected from the group consisting of SEQ ID NOs: 1-8, 10-15, 19-23, 25, and 28, wherein at least one of said antigens comprises a Chlamydia trachomatis -specific CT456-TARP antigen selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO:23 and SEQ ID NO: 25.
2. A method for the selective detection of Chlamydia trachomatis infections and the serological differentiation among acute Chlamydia pneumoniae infection, acute Chlamydia trachomatis infection and chronic Chlamydia trachomatis infection, said method comprising the step of detecting antibodies in a sample using the test kit of claim 8 .
3. The method as claimed in claim 2 , wherein said step of detecting antibodies in a sample uses at least three antigens.
4. The method as claimed in claim 2 , characterized in that the method of detection of the antibodies comprises the detection of an antigen/antibody complex.
5. The method as claimed in claim 2 , characterized in that the method of detection of the antibodies utilizes an ELISA (enzyme-linked immunosorbent assay) test method, Western blot or line assay.
6. A biochip for the selective detection of Chlamydia trachomatis infections and the serologic differentiation among acute Chlamydia pneumoniae infection, acute Chlamydia trachomatis infection and chronic Chlamydia trachomatis infection, said biochip comprising two to seven antigens selected from the group consisting of SEQ ID NOs: 1-8, 10-15, 19-23, 25, and 28, wherein at least one of said antigens comprises a Chlamydia trachomatis -specific CT456-TARP antigen selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO:23 and SEQ ID NO: 25.
7. The biochip as claimed in claim 6 , wherein said biochip comprises CT017 (SEQ ID NO: 1), CT098 (SEQ ID NO: 2), CT318-L1P (SEQ ID NO: 3), CT431 (SEQ ID NO: 4), CT456-TARP (SEQ ID NO: 5), CT603-TSAP (SEQ ID NO: 6) and CT664 (SEQ ID NO: 7).
8. The biochip as claimed in claim 6 , characterized in that the Chlamydia trachomatis -specific antigens are applied at a site of a membrane of the biochip, which is spatially separated from other sites on the membrane, on which other antigens are applied.
9. The biochip as claimed in claim 6 , characterized in that, spatially separately from the Chlamydia trachomatis -specific antigens, other antigens are applied on the membrane, which permit specific detection against Chlamydia pneumonia or Chlamydia pittance.
10. A method for the selective detection of Chlamydia trachomatis infections and the serological differentiation among acute Chlamydia pneumoniae infection, acute Chlamydia trachomatis infection and chronic Chlamydia trachomatis infection, said method comprising the step of detecting antibodies in a sample using the biochip of claim 6 .